Trial · NCT01742117
Tailored Antiplatelet Therapy Following PCI
NCT01742117, Phase 4, Completed, Mayo Clinic; results first posted 2021-11-09
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Tailored Antiplatelet Therapy Following PCI. Trials, record NCT01742117. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01742117
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tailored Antiplatelet Therapy Following PCI
- NCT number
- NCT01742117
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 5,276 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Coronary Artery Disease, Acute Coronary Syndrome, Stenosis
- Interventions
- Clopidogrel, Ticagrelor
- First posted
- 2012-12-05
- Last updated
- 2021-11-09
- Results first posted
- 2021-11-09
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. | 1 year after percutaneous coronary intervention (PCI) | Number of subjects who experienced major adverse cardiovascular event as defined as cardiovascular death, myocardial infarction, stroke, severe recurrent ischemia, and stent thrombosis in subjects identified as CPY2C19 LOF carriers by TaqMan. |
| Primary | Occurrence of the a Major Adverse Cardiovascular Event | Approximately 3 years after percutaneous coronary intervention (PCI) | Number of subjects to experience a major adverse cardiovascular event as defined as cardiovascular death, myocardial infarction, stroke, severe recurrent ischemia, and stent thrombosis. |
| Secondary | Thrombolysis in Myocardial Infarction Major or Minor Bleeding in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. | 1 year after percutaneous coronary intervention (PCI) | Number of subjects that experienced thrombolysis in myocardial infarction major or minor bleeding in subjects identified as CYP2C19 LOF carriers by TaqMan |
| Secondary | Thrombolysis in Myocardial Infarction Major or Minor Bleeding | Approximately 3 years after percutaneous coronary intervention (PCI) | Number of subjects that experienced thrombolysis in myocardial infarction major or minor bleeding |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. | 1 year after percutaneous coronary intervention (PCI) | For 1 year endpoint in Genotype-Guided Therapy arm 1738 were excluded from data analysis due Identified as CYP2C19 LOF noncarriers by TaqMan or no TaqMan results available. For 1 year endpoint in Conventional Therapy arm 1689 were excluded from data analysis due Identified as CYP2C19 LOF noncarriers by TaqMan or no TaqMan results available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Thrombolysis in Myocardial Infarction Major or Minor Bleeding in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. | 1 year after percutaneous coronary intervention (PCI) | For 1 year endpoint in Genotype-Guided Therapy arm 1738 were excluded from data analysis due Identified as CYP2C19 LOF noncarriers by TaqMan or no TaqMan results available. For 1 year endpoint in Conventional Therapy arm 1689 were excluded from data analysis due Identified as CYP2C19 LOF noncarriers by TaqMan or no TaqMan results available. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Thrombolysis in Myocardial Infarction Major or Minor Bleeding | Approximately 3 years after percutaneous coronary intervention (PCI) | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Occurrence of the a Major Adverse Cardiovascular Event | Approximately 3 years after percutaneous coronary intervention (PCI) | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. | Genotype-Guided Therapy | 35 | Participants | ||
| Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. | Conventional Therapy | 54 | Participants | ||
| Thrombolysis in Myocardial Infarction Major or Minor Bleeding in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. | Genotype-Guided Therapy | 16 | Participants | ||
| Thrombolysis in Myocardial Infarction Major or Minor Bleeding in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. | Conventional Therapy | 14 | Participants | ||
| Thrombolysis in Myocardial Infarction Major or Minor Bleeding | Genotype-Guided Therapy | 54 | Participants | ||
| Thrombolysis in Myocardial Infarction Major or Minor Bleeding | Conventional Therapy | 53 | Participants | ||
| Occurrence of the a Major Adverse Cardiovascular Event | Genotype-Guided Therapy | 262 | Participants | ||
| Occurrence of the a Major Adverse Cardiovascular Event | Conventional Therapy | 269 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Genotype-Guided Therapy | 2,641 | |
| Overall Study | STARTED | Conventional Therapy | 2,635 | |
| Overall Study | COMPLETED | Genotype-Guided Therapy | 2,641 | |
| Overall Study | COMPLETED | Conventional Therapy | 2,635 | |
| Overall Study | NOT COMPLETED | Genotype-Guided Therapy | 0 | |
| Overall Study | NOT COMPLETED | Conventional Therapy | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Genotype-Guided Therapy | 95 | 2,641 |
| Total, all-cause mortality | Conventional Therapy | 98 | 2,635 |
| Total, other adverse events | Genotype-Guided Therapy | 0 | 2,641 |
| Total, other adverse events | Conventional Therapy | 0 | 2,635 |
| Total, serious adverse events | Genotype-Guided Therapy | 0 | 2,641 |
| Total, serious adverse events | Conventional Therapy | 0 | 2,635 |
Source ClinicalTrials.gov
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01HL128606 | Clinical Implementation of Clopidogrel Pharmacogenetics: The TAILOR-PCI Trial - CCC - Lead Application | PEREIRA, NAVEEN LUKE; FARKOUH, MICHAEL E | MAYO CLINIC ROCHESTER | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2016 to 2019 |
Source NIH RePORTER
Trial comparisons6
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Genotype-Guided Therapy vs Conventional Therapy: Occurrence of the a Major Adverse Cardiovascular Event | Trial comparisons |
| Genotype-Guided Therapy vs Conventional Therapy: Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. | Trial comparisons |
| Genotype-Guided Therapy vs Conventional Therapy: Thrombolysis in Myocardial Infarction Major or Minor Bleeding | Trial comparisons |
| Genotype-Guided Therapy vs Conventional Therapy: deaths from any cause | Trial comparisons |
| Genotype-Guided Therapy vs Conventional Therapy: Thrombolysis in Myocardial Infarction Major or Minor Bleeding in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. | Trial comparisons |
| Genotype-Guided Therapy vs Conventional Therapy: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01742117
GET https://conductscience.org/api/trials/v1/NCT01742117/registered